ASP Isotopes (NASDAQ:ASPI) Announces Earnings Results, Misses Expectations By $0.11 EPS

ASP Isotopes (NASDAQ:ASPI) posted its quarterly earnings data on Friday. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.11), Zacks reports. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

ASP Isotopes Stock Performance

ASPI traded down $0.01 during midday trading on Friday, reaching $4.27. The company had a trading volume of 1,941,410 shares, compared to its average volume of 4,927,466. ASP Isotopes has a 12-month low of $3.51 and a 12-month high of $14.49. The business has a 50-day moving average price of $5.23 and a two-hundred day moving average price of $5.44. The stock has a market cap of $654.63 million, a PE ratio of -2.05 and a beta of 3.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, ASP Isotopes presently has a consensus rating of “Hold” and a consensus target price of $13.00.

Insider Buying and Selling at ASP Isotopes

In other news, Director Michael Gorley sold 30,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $6.27, for a total transaction of $188,100.00. Following the transaction, the director owned 87,908 shares of the company’s stock, valued at $551,183.16. This represents a 25.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Heather Kiessling sold 23,124 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $6.28, for a total transaction of $145,218.72. Following the sale, the chief financial officer owned 1,526,252 shares in the company, valued at $9,584,862.56. The trade was a 1.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 279,079 shares of company stock valued at $2,049,208 in the last quarter. Insiders own 14.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in ASP Isotopes by 9.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock valued at $148,000 after buying an additional 2,709 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of ASP Isotopes by 20.9% in the second quarter. Rhumbline Advisers now owns 78,994 shares of the company’s stock worth $581,000 after buying an additional 13,668 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of ASP Isotopes in the second quarter worth about $178,000. New York State Common Retirement Fund boosted its position in shares of ASP Isotopes by 418.2% in the second quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock valued at $126,000 after acquiring an additional 13,800 shares during the period. Finally, Invesco Ltd. boosted its position in shares of ASP Isotopes by 2,205.0% in the second quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock valued at $3,468,000 after acquiring an additional 450,776 shares during the period. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.